|
|
 Previous Article | Table of Contents | Next Article 
Blood, 15 November 2000, Vol. 96, No. 10, pp. 3374-3380
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
Evaluation and clinical correlations of bone marrow
angiogenesis in myelofibrosis with myeloid metaplasia
Ruben A. Mesa,
Curtis A. Hanson,
S. Vincent Rajkumar,
Georgene Schroeder, and
Ayalew Tefferi
From the Division of Hematology and Internal Medicine,
the Division of Hematopathology, and the Cancer Center Statistics Unit,
Mayo Clinic and Mayo Foundation, Rochester, MN.
Recent observations have underscored the biologic relevance of
intratumoral angiogenesis and its potential impact on prognosis. Increased bone marrow angiogenesis has been demonstrated in a variety
of hematologic disorders, including multiple myeloma. The extent and
prognostic significance of bone marrow angiogenesis in 114 patients
with myelofibrosis with myeloid metaplasia (MMM) was investigated. A
control group of 44 patients without bone marrow disease, 15 patients
with polycythemia vera, and 17 patients with essential thrombocythemia
was also studied. Bone marrow microvessel density was assessed by a
semiquantitative method, visual microvessel grading, and 2 separate
quantitative methods, visual count and computerized image analysis.
Angiogenesis estimation by all 3 methods was highly comparable. On
visual microvessel grading, a grade 3 or 4 increase in bone marrow
angiogenesis was demonstrated in 70% of patients with MMM, 33% of
patients with polycythemia vera, 12% of patients with essential
thrombocythemia, and 0% of normal controls. In a multivariate
analysis, increased angiogenesis in MMM correlated significantly with
increased spleen size and was found to be a significant and independent
risk factor for overall survival. Increases in marrow angiogenesis
correlated with hypercellularity and megakaryocyte clumping. In
contrast, these 2 features were inversely proportional to reticulin
fibrosis, whereas increases in marrow angiogenesis were independent of
reticulin fibrosis. These preliminary findings suggest that
neo-angiogenesis is an integral component of the bone marrow stromal
reaction in MMM and may provide useful prognostic information and a
rationale for the therapeutic investigation of anti-angiogenic agents.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. A. Burger, P. Ghia, A. Rosenwald, and F. Caligaris-Cappio
The microenvironment in mature B-cell malignancies: a target for new treatment strategies
Blood,
October 15, 2009;
114(16):
3367 - 3375.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Quintas-Cardama, H. M. Kantarjian, T. Manshouri, D. Thomas, J. Cortes, F. Ravandi, G. Garcia-Manero, A. Ferrajoli, C. Bueso-Ramos, and S. Verstovsek
Lenalidomide Plus Prednisone Results in Durable Clinical, Histopathologic, and Molecular Responses in Patients With Myelofibrosis
J. Clin. Oncol.,
October 1, 2009;
27(28):
4760 - 4766.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A M Florena, C Tripodo, A Di Bernardo, E Iannitto, C Guarnotta, R Porcasi, S Ingrao, V Abbadessa, and V Franco
Different immunophenotypical apoptotic profiles characterise megakaryocytes of essential thrombocythaemia and primary myelofibrosis
J. Clin. Pathol.,
April 1, 2009;
62(4):
331 - 338.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Tripodo, A. Di Bernardo, M. P. Ternullo, C. Guarnotta, R. Porcasi, S. Ingrao, U. Gianelli, E. Boveri, E. Iannitto, G. Franco, et al.
CD146+ bone marrow osteoprogenitors increase in the advanced stages of primary myelofibrosis
Haematologica,
January 1, 2009;
94(1):
127 - 130.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Weinkove, J. T. Reilly, M. F. McMullin, N. J. Curtin, D. Radia, and C. N. Harrison
Low-dose thalidomide in myelofibrosis
Haematologica,
July 1, 2008;
93(7):
1100 - 1101.
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Wagner-Ballon, D. F. Pisani, T. Gastinne, M. Tulliez, R. Chaligne, C. Lacout, F. Aurade, J.-L. Villeval, P. Gonin, W. Vainchenker, et al.
Proteasome inhibitor bortezomib impairs both myelofibrosis and osteosclerosis induced by high thrombopoietin levels in mice
Blood,
July 1, 2007;
110(1):
345 - 353.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tefferi
Primary myelofibrosis and its paraneoplastic stromal effects
Haematologica,
May 1, 2007;
92(5):
577 - 579.
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. A. Avramis, E. H. Panosyan, F. Dorey, J. S. Holcenberg, and V. I. Avramis
Correlation between High Vascular Endothelial Growth Factor-A Serum Levels and Treatment Outcome in Patients with Standard-Risk Acute Lymphoblastic Leukemia: A Report from Children's Oncology Group Study CCG-1962
Clin. Cancer Res.,
December 1, 2006;
12(23):
6978 - 6984.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Arana-Yi, A. Quintas-Cardama, F. Giles, D. Thomas, A. Carrasco-Yalan, J. Cortes, H. Kantarjian, and S. Verstovsek
Advances in the Therapy of Chronic Idiopathic Myelofibrosis
Oncologist,
September 1, 2006;
11(8):
929 - 943.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tefferi, G. Barosi, R. A. Mesa, F. Cervantes, H. J. Deeg, J. T. Reilly, S. Verstovsek, B. Dupriez, R. T. Silver, O. Odenike, et al.
International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT)
Blood,
September 1, 2006;
108(5):
1497 - 1503.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tefferi, J. Cortes, S. Verstovsek, R. A. Mesa, D. Thomas, T. L. Lasho, W. J. Hogan, M. R. Litzow, J. B. Allred, D. Jones, et al.
Lenalidomide therapy in myelofibrosis with myeloid metaplasia
Blood,
August 15, 2006;
108(4):
1158 - 1164.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Bock, J. Neuse, K. Hussein, K. Brakensiek, G. Buesche, T. Buhr, B. Wiese, and H. Kreipe
Aberrant Collagenase Expression in Chronic Idiopathic Myelofibrosis Is Related to the Stage of Disease but Not to the JAK2 Mutation Status
Am. J. Pathol.,
August 1, 2006;
169(2):
471 - 481.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Fureder, M.-T. Krauth, W. R. Sperr, K. Sonneck, I. Simonitsch-Klupp, L. Mullauer, M. Willmann, H.-P. Horny, and P. Valent
Evaluation of Angiogenesis and Vascular Endothelial Growth Factor Expression in the Bone Marrow of Patients with Aplastic Anemia
Am. J. Pathol.,
January 1, 2006;
168(1):
123 - 130.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Gerli, C. Vanelli, O. Turri, M. Erario, A. Gardellini, M. Pugliano, and M. L. Biondi
SDF1-3'A Gene Polymorphism Is Associated with Chronic Myeloproliferative Disease and Thrombotic Events
Clin. Chem.,
December 1, 2005;
51(12):
2411 - 2414.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tefferi
Pathogenesis of Myelofibrosis With Myeloid Metaplasia
J. Clin. Oncol.,
November 20, 2005;
23(33):
8520 - 8530.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Massa, V. Rosti, I. Ramajoli, R. Campanelli, A. Pecci, G. Viarengo, V. Meli, M. Marchetti, R. Hoffman, and G. Barosi
Circulating CD34+, CD133+, and Vascular Endothelial Growth Factor Receptor 2-Positive Endothelial Progenitor Cells in Myelofibrosis With Myeloid Metaplasia
J. Clin. Oncol.,
August 20, 2005;
23(24):
5688 - 5695.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Podar and K. C. Anderson
The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications
Blood,
February 15, 2005;
105(4):
1383 - 1395.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kumar, T. E. Witzig, M. Timm, J. Haug, L. Wellik, T. K. Kimlinger, P. R. Greipp, and S. V. Rajkumar
Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression
Blood,
August 15, 2004;
104(4):
1159 - 1165.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. T. Silver
Myelofibrosis: Thalidomide Finds a New Disease
Mayo Clin. Proc.,
July 1, 2004;
79(7):
857 - 858.
[PDF]
|
|
|
|
|
|
|
S. Kumar, T. E. Witzig, and S. V. Rajkumar
Thalidomide: Current Role in the Treatment of Non-Plasma Cell Malignancies
J. Clin. Oncol.,
June 15, 2004;
22(12):
2477 - 2488.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. M. Kvasnicka, J. Thiele, P. Staib, A. Schmitt-Graeff, M. Griesshammer, J. Klose, K. Engels, and S. Kriener
Reversal of bone marrow angiogenesis in chronic myeloid leukemia following imatinib mesylate (STI571) therapy
Blood,
May 1, 2004;
103(9):
3549 - 3551.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. O'Brien, A. Tefferi, and P. Valent
Chronic Myelogenous Leukemia and Myeloproliferative Disease
Hematology,
January 1, 2004;
2004(1):
146 - 162.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tefferi
The Forgotten Myeloproliferative Disorder: Myeloid Metaplasia
Oncologist,
June 1, 2003;
8(3):
225 - 231.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Mesa, D. P. Steensma, A. Pardanani, C.-Y. Li, M. Elliott, S. H. Kaufmann, G. Wiseman, L. A. Gray, G. Schroeder, T. Reeder, et al.
A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia
Blood,
April 1, 2003;
101(7):
2534 - 2541.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kumar, R. Fonseca, A. Dispenzieri, M. Q. Lacy, J. A. Lust, L. Wellik, T. E. Witzig, M. A. Gertz, R. A. Kyle, P. R. Greipp, et al.
Prognostic value of angiogenesis in solitary bone plasmacytoma
Blood,
March 1, 2003;
101(5):
1715 - 1717.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Spivak, G. Barosi, G. Tognoni, T. Barbui, G. Finazzi, R. Marchioli, and M. Marchetti
Chronic Myeloproliferative Disorders
Hematology,
January 1, 2003;
2003(1):
200 - 224.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Pardanani, J.-Y. Baek, C.-Y. Li, J. H. Butterfield, and A. Tefferi
Systemic Mast Cell Disease Without Associated Hematologic Disorder: A Combined Retrospective and Prospective Study
Mayo Clin. Proc.,
November 1, 2002;
77(11):
1169 - 1175.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. A. Mesa, C. A. Hanson, C.-Y. Li, S.-Y. Yoon, S. V. Rajkumar, G. Schroeder, and A. Tefferi
Diagnostic and prognostic value of bone marrow angiogenesis and megakaryocyte c-Mpl expression in essential thrombocythemia
Blood,
May 13, 2002;
99(11):
4131 - 4137.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Wimazal, J.-H. Jordan, W. R. Sperr, A. Chott, S. Dabbass, K. Lechner, H. P. Horny, and P. Valent
Increased Angiogenesis in the Bone Marrow of Patients with Systemic Mastocytosis
Am. J. Pathol.,
May 1, 2002;
160(5):
1639 - 1645.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Barosi, G. Viarengo, A. Pecci, V. Rosti, G. Piaggio, M. Marchetti, and F. Frassoni
Diagnostic and clinical relevance of the number of circulating CD34+ cells in myelofibrosis with myeloid metaplasia
Blood,
December 1, 2001;
98(12):
3249 - 3255.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. F. List
Vascular Endothelial Growth Factor Signaling Pathway as an Emerging Target in Hematologic Malignancies
Oncologist,
October 1, 2001;
6(2008):
24 - 31.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. J. Giles
The Vascular Endothelial Growth Factor (VEGF) Signaling Pathway: A Therapeutic Target in Patients with Hematologic Malignancies
Oncologist,
October 1, 2001;
6(2008):
32 - 39.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J. Klasa, A. F. List, and B. D. Cheson
Rational Approaches to Design of Therapeutics Targeting Molecular Markers
Hematology,
January 1, 2001;
2001(1):
443 - 462.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tefferi and M. A. Elliott
Serious myeloproliferative reactions associated with the use of thalidomide in myelofibrosis with myeloid metaplasia
Blood,
December 1, 2000;
96(12):
4007 - 4007.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tefferi, R. A. Mesa, L. A. Gray, D. P. Steensma, J. K. Camoriano, M. A. Elliott, A. Pardanani, S. M. Ansell, T. G. Call, G. Colon-Otero, et al.
Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia
Blood,
May 15, 2002;
99(10):
3854 - 3856.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
